Caribou Biosciences, Inc. announced a strategic shift focusing on its lead oncology programs, CB-010 and CB-011, involving workforce and cost reductions aimed at extending its cash runway into the ...

BOSTON, July 25, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and ...

Highest priority programs – BEAM-101 and ESCAPE for sickle cell disease and BEAM-302 for alpha-1 antitrypsin deficiency – expected to provide foundation for meaningful value creation Company to ...

-- CB-010 ANTLER 2L LBCL Phase 1 dataset expected to include at least six months of follow up on the majority of patients; ongoing interactions with FDA on potential pivotal trial design -- -- CB-011 ...

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), today announced strategic prioritization of late-stage ocular disease programs in allergic conjunctivitis, dry ...

As of December 31, 2021, Silverback reported cash, cash equivalents, restricted cash, and investments of $319.1 million, compared to cash and cash equivalents of $386.6 million at December 31, 2020, ...

The human genome contains approximately 1,600 types of transcription factors responsible for regulating gene activity across more than 400 tissue and cell types. Chromatin immunoprecipitation ...

The recent announcement of deeper ties between Russia and China aligned against the United States and a major gas deal settled in euros signal the depths of strategic failure in Washington. Every ...

If you’ve ever sat through a death-by-PowerPoint strategy presentation, you know the pain. Most leadership teams go too deep with their strategic plans. Traditional plans are bloated. They’re loaded ...

Douglas, a technical analyst, came to me having gained extensive experience within a niche market, seeking to transition into an analyst or market research role. He had developed a two-page resume ...